Atossa Therapeutics (ATOS) Net Equity Issued and Repurchased (2013 - 2016)

Atossa Therapeutics (ATOS) has reported Net Equity Issued and Repurchased for 4 consecutive years, with -$32563.0 the latest figure, recorded in Q2 2016.

• In Q2 2016, Net Equity Issued and Repurchased fell 100.62% year-over-year to -$32563.0; the TTM figure through Jun 2016 stood at $2.1 million (down 78.37% YoY), while the FY2020 annual figure was $140000.0, changed N/A from the prior year.
• Net Equity Issued and Repurchased eased to -$32563.0 in Q2 2016 per ATOS's latest filing, from $2.2 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $5.2 million in Q2 2015 and bottomed at -$41665.0 in Q4 2015.
• Historically, Net Equity Issued and Repurchased has averaged $1.8 million across 4 years, with a median of $1.2 million in 2014.
• Annual changes were most pronounced in 2015 — Net Equity Issued and Repurchased tumbled 103.09% — and 2016, when it slumped 49.53%.
• Atossa Therapeutics' Net Equity Issued and Repurchased stood at $3.0 million in 2013, then sank by 94.95% to $150000.0 in 2014, then slumped by 127.78% to -$41665.0 in 2015, then gained by 21.85% to -$32563.0 in 2016.
• Business Quant data shows ATOS's Net Equity Issued and Repurchased at -$32563.0 in Q2 2016, $2.2 million in Q1 2016, and -$41665.0 in Q4 2015.